Background: studies of bimonthly 48-hour regimens of highdose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS). To help define the optimal dose schedule for oxaliplatin in pretreated metastatic colorectal cancer, we retrospectively analyzed data from three phase II studies using different FOLFOX regimens (FOLFOX2, 3 and 6).
Introduction
Oxaliplatin is a novel 1,2-diaminocyclohexane platinum derivative with a favourable safety and tolerability profile [1] . The recent introduction of oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of metastatic colorectal cancer has consistently increased objective response rates to over 40%, even in 5-FU refractory disease [2] [3] [4] .
We have developed a bimonthly 48-hour regimen combining LV and continuous infusion of 5-FU that allows higher doses of 5-FU than an LV-5-FU bolus regimen, with a higher response rate, less toxicity and potential for combination with other modulators or drugs [2, 5, 6] . Based on these findings and promising preclinical and clinical evidence of potentiation between oxaliplatin and 5-FU [7, 8] , we have studied various bimonthly 48-hour regimens of high-dose LV (FOLinic acid), 5-FU by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer [2, [9] [10] [11] . These regimens, which include FOLFOX2, FOLFOX3 and FOLFOX6, involve different doses and schedules of LV, 5-FU and/or oxaliplatin. Response rates for the FOLFOX2, FOLFOX3 and FOLFOX6 regimens have ranged from 20% to 46% [2, [9] [10] [11] . The higher response rate with FOLFOX2 (46%) versus FOLFOX3 (20%), which differed only in terms of oxaliplatin dose (100 mg/m 2 and 85 mg/m 2 , respectively) suggested that an important prognostic factor might be oxaliplatin dose intensity.
Dose-intensification of chemotherapeutic agents has been studied in clinical trials since the mid-1980s. Dose intensity describes the drug dose delivered per unit time and is generally expressed as milligrams per square meter per week, regardless of the schedule used [12] . The concept of dose intensity allows the dose-response relationship for a given drug to be evaluated across different combinations and schedules [13] . Retrospective analyses show that dose intensity, particularly the amount of drug actually received (received dose intensity), is an important prognostic factor for some drugs or combinations in some diseases [14] . For breast, ovarian and 2 ), and (c) FOLFOX6 (simplified LV-5FU + oxaliplatin, 100 mg/m 2 ). Oxaliplatin was given as a two-hour infusion on day 1 (Dl). Cycles were repeated every two weeks.
small-cell lung cancers, a significant dose-response effect has been observed in some, but not all, comparative studies, although the effect on survival has been limited [15] [16] [17] .
With respect to gastrointestinal neoplasia, retrospective analyses show a dose-intensity effect in patients receiving first-line 5-FU for advanced gastric carcinoma [18] and advanced colorectal cancer [19] . In addition, dose-intensity of 5-FU and mitomycin C was prognostic for disease-free survival in patients with anal canal carcinoma treated by chemoradiotherapy [20] .
To define further the optimal dose schedule for oxaliplatin in pretreated metastatic colorectal cancer, we evaluated whether oxaliplatin dose-intensity is a prognostic factor for response rate and progression-free survival (PFS). Our study involved a retrospective analysis of data from three phase II studies using the FOLFOX2, FOLFOX3 and FOLFOX6 regimens.
Patients and methods
The protocols of all three studies were approved by the Ethics Review Committees of the participating centres, and written informed consent was obtained from every patient before entry into the studies. patients received FOLFOX2 and 10 patients received FOLFOX3. Thus, a total of 161 cases were evaluated for potential inclusion in the present analysis. The methods of each study have been reported previously [2, 9, 11] .
Treatment regimens for FOLFOX2, 3 and 6 Figure 1 summarises the treatment regimens used in the three studies. FOLFOX2 comprised oxaliplatin 100 mg/m 2 as a 2-hour infusion on day 1 only; and, on both days 1 and 2, LV 500 mg/m 2 as a 2-hour infusion, followed by 5-FU 1500-2000 mg/m 2 by 22-hour infusion. This regimen was repeated every two weeks. FOLFOX3 was the same bimonthly regimen, except that oxaliplatin was given at a lower dose of 85 mg/m 2 as a two-hour infusion.
In FOLFOX6 a higher dose of oxaliplatin was added to a new simplified bimonthly LV-5-FU regimen [21] [22] [23] -oxaliplatin 100 mg/m 2 and LV 400 mg/m 2 as 2-hour infusions on day 1 only, followed by 5-FU bolus 400 mg/m 2 and 5-FU 2,400-3,000 mg/m 2 as a 46-hour infusion (over day 1 and 2). The scheduled dose intensity was similar in the FOLFOX2 and FOLFOX6 regimens, but dose modification differed if toxicity was apparent. If toxicity of at least grade 2 occurred in the FOLFOX2 study, only the 5-FU dose was reduced. However, in the FOLFOX6 study, the dose of oxaliplatin was also reduced, to 75 mg/m 2 .
Dose intensity analysis
The present analysis included all patients who received at least four consecutive cycles of chemotherapy. Cycles could be consecutive or non-consecutive, in most cases toxicity being the reason for delaying cycles of treatment. Received dose intensity was calculated using a model similar to that proposed by Hryniuk's group [13] . Oxaliplatin dose-intensity over a two-week period was calculated on a per patient basis from the date of cycle 1 to the date of cycle 5 in patients who received more than four cycles or to the date of cycle 4 plus the estimated fourth interval (equal to one-third of the interval between cycles one and four) in patients who received only four cycles. As the recommended dose in first-line therapy was 85 mg/m 2 /2 weeks [24] , patients were then grouped into those who had received an oxaliplatin dose intensity of $ 85 mg/m 2 /2 weeks ('low-dose intensity' -LDI) and those who had received > 85 mg/m 2 /2 weeks ('high-dose intensity' -HDI), and mean dose intensity was calculated for these groups of patients.
Response rate was evaluated according to dose intensity of oxaliplatin. The chi-square test or Fisher's exact test were used for comparisons of population and risk ratio (RR). PFS was calculated from the date of the first cycle of FOLFOX using the Kaplan-Meier method. The log-rank test was used for PFS comparisons. Stepwise analyses were undertaken to identify potential prognostic factors for PFS using the Cox proportional hazards model. Variables considered for inclusion in the model were sex, age, performance status, primary site of disease, number of organs involved, baseline measurements for alkaline phosphatase (ALP), lactate dehydrogenase (LDH), carcinoembryogenic antigen (CEA), number of line of treatment, resistance or refractoriness to LV-5-FU, response to previous chemotherapy and oxaliplatin dose intensity. A multivariate analysis using the Cox model [25] was also performed.
Inclusion criteria for FOLFOX2, 3 and 6.
All three studies were performed in the same centres and involved patients with metastatic colorectal cancer who had progressed on an LV-5-FU regimen as first-or second-line treatment, or as third line treatment in up to 22% of patients. Patients had a WHO performance status of 0-2 and were aged between 18 and 75 years in the FOLFOX2 and 3 studies, and there was no maximum age in FOLFOX6. The number of patients in each study was 46, 30, and 60 for FOLFOX2, 3, and 6, respectively. After the studies were completed, an additional 15
Results
The results of the FOLFOX2, 3, and 6 studies are already published and are summarised in Table 1 [2, 9, 11] .
Of a total of 161 patients who received the FOLFOX2, 3, and 6 regimens, 126 were eligible for inclusion in the dose-intensity analysis (45, 28 and 53 patients in each study, respectively). Median oxaliplatin dose intensities Abbreviation: n -total number of patients. " Grade 2-3. were observed in 31 (39%) patients in the HDI group and 9 (19%) patients in the LDI group (P -0.03). Stable disease was present in 37 (47%) patients in the HDI group and 27 (57%) patients in the LDI group; disease progressed in 11 (14%) patients in the HDI group and 11 (23%) patients in the LDI group.
The median PFS from day 1 of FOLFOX therapy in patients receiving HDI oxaliplatin treatment was 28 weeks, with 52% of patients progression free at 6 months ( Figure 2 ). In contrast, the median PFS for patients in the LDI group was 26 weeks with 36% remaining progression free at 6 months (P = 0.02). No significant difference was observed in overall survival. Median overall survival was 67 weeks (69% alive at 12 months) in patients receiving HDI oxaliplatin versus 44 weeks (44% alive at 12 months) for those receiving LDI treatment (P -0.07).
Prognostic factors
The two groups did not differ significantly in terms of patient characteristics, including age, primary site (colon or rectum) number of metastatic sites, performance status, serum carcinoembryonic antigen (CEA) and alkaline phosphatase levels, or increase in serum lactate dehydrogenase (LDH) level (Table 3) . Furthermore, there was no significant difference between groups in response to first-line therapy, the number of patients receiving FOLFOX as second-or third-line treatment, or in the received dose intensity of 5-FU.
In addition to oxaliplatin dose intensity, only two prognostic factors were identified by univariate analysis: performance status 0 vs. 1 and 2 (P = 0.012), and patient status (LV-5-FU refractory vs. resistant (P = 0.022). FOLFOX second-line vs. third-line treatment was of borderline significance (P = 0.06) ( Table 4 ). In the multivariate analysis, independent prognostic factors were performance status (P -0.0146, RR = 1.598) and patient status (P = 0.0240, RR = 0.654. Oxaliplatin dose intensity was borderline (P -0.0704, RR = 0.702).
Toxicity
There was no association between oxaliplatin dose intensity and toxicity (Table 5 ). The most frequent grade Table 3 . Patients' characteristics in low-dose intensity and high-dose intensity groups. (32) 22 (47) 32 (68) 21 (46) 21 (54) 23 (62) 39 (83) 8 (17) (36) 32 (44) 36 (51) 61 (77) 18 (22) 53 (67) 26 (33) 21 (27) 59 ( 3-4 toxicity was neutropenia, which was more common in the LDI group (38% of patients vs. 24%; P = 0.23. However, grade 3 neutropenia was the reason for most treatment delays and therefore reductions in oxaliplatin dose intensity.
High oxaliplatin dose intensity was not associated with a significant increase in the incidence of grade 3 neurotoxicity (14% of patients versus 8% in the LDI group; P -0.66).
Discussion
Combination chemotherapy and dose of medication are the major variables for the clinical use of antitumour agents [26] . An important rationale for using combination therapy is to overcome tumour cell heterogeneity and reduce the risk of drug resistance [26] [27] [28] . A key principle underlying dose intensity is an increase in log tumour cell kill, although the precise dose-response relationships for most human tumours are poorly understood [16, [26] [27] [28] [29] [30] [31] . In addition, a significant increase in dose delivery and drug exposure can overcome drug resistance in tumour cells in vitro and in vivo [14, 32] .
In advanced colorectal cancer, a review of 28 randomised trials and one non-randomised trial showed a strong relationship between dose intensity of 5-FU and response rate in previously untreated patients [19] . An increase of only 100 mg/m 2 /week of received dose intensity of 5-FU given by i.v. bolus increased the response rate by 45% (from 20% to 29%). However, Cascinu et al. conducted a phase II clinical trial and a review of five other studies, which showed no significant dose intensity/response effect with LV-5-FU in previously untreated advanced colorectal cancer [33] .
For oxaliplatin, in vitro data demonstrate that response rate has a clear relationship with length of exposure and concentration in a variety of human tumour colony-forming units, including colon, gastric and non-small-cell lung cancers, and melanoma [34] . Additionally, in clones resistant to a range of conventional chemotherapy agents -including 5-FU, cisplatin, carboplatin, irinotecan, paclitaxel and doxorubicin -significant responses to oxaliplatin were observed that were both concentration and time dependent [34] .
As for the clinical setting, our analysis demonstrates a relationship between high oxaliplatin dose intensity and response rate and PFS in patients with pretreated colorectal cancer. Apart from oxaliplatin dose intensity, only performance status and the patient status correlated significantly with PFS. However, our results are consistent with those of another recent retrospective analysis of four trials involving 381 previously untreated patients with advanced disease who received oxaliplatin and LV-5-FU delivered by constant rate infusion or chronotherapy [35] . The analysis showed significant correlation between the dose intensity (over two months) of oxaliplatin or 5-FU and complete post-surgical response rate. There was a trend toward a relationship between dose intensity and survival, although this did not achieve statistical significance.
Retrospective analyses of outcome in relation to dose intensity are potentially flawed in that, unless the duration of treatment is controlled, it is impossible to distinguish between total dose and dose intensity [13] . Also, for responders who go on to receive further cycles, dose intensity would tend to fall with time due to cumulative toxicity. Hryniuk and Goodyear suggested that, in a retrospective analysis, the most practical method for fixing the total amount of drug received, is to specify the number of cycles to be analysed based on a judgement of what constitutes a fair test of the treatment with respect to the selected outcome measure [13] . We chose to fix the number of cycles at four, corresponding to the time of the first tumour evaluation.
Furthermore, we attempted to avoid a number of other pitfalls associated with the study of dose intensity. Firstly, the use of received dose intensity in our analysis, as opposed to scheduled (intended) dose intensity is more useful because it accommodates the impact of dose reductions and treatment delays needed in actual practice [36] . And, in fact, the difference in the received dose intensity of the FOLFOX2 and FOLFOX6 studies highlights the importance of individual dose adaptation. Secondly, because dose intensity should be regarded primarily as a feature of an individual patient's treatment course [13] , we evaluated received dose intensity on a per-patient basis and averaged across patients rather than across cycles. Averaging across cycles tends to obscure any within-study relationship between received dose intensity and outcome for individual patients or groups of patients [13] .
A potential source of bias in dose-intensity analyses is that sicker patients are more likely to have their dose reduced or delayed [37] . This may produce an association between low received dose intensity and poorer outcome that is not due to a dose-response effect [38, 39] . In the present study, however, there was no significant difference between the HDI and LDI groups in terms of performance status or number of metastatic sites.
Our analysis showed that high oxaliplatin dose intensity is not associated with an increase in toxicity. Neutropenia, which is associated with 5-FU treatment, was the most frequent grade 3 toxicity. Neutropenia explained most treatment delays and most decreases in dose intensity, and underlies the increased frequency of grade 3 neutropenia observed in the LDI group. No significant increase was seen in the incidence of grade 3 neurotoxicity in patients who received a high-dose intensity of oxaliplatin. Reversible peripheral neuropathy is the dose-limiting toxicity of oxaliplatin. A clearly defined maximal tolerated dose (MTD) has not been established for oxaliplatin, but is estimated to be approximately 200 mg/m 2 [1] . However, total cumulative dose is more predictive of oxaliplatin-induced neurotoxicity than MTD [1, 40] .
The FOLFOX combination regimens currently undergoing investigation address important factors essential to defining the optimum oxaliplatin dose schedule. These factors include haematological toxicity and cumulative neurotoxicity. Haematological toxicity, a recognised side effect of 5-FU treatment, can usually be controlled by dose reduction, while neurotoxicity is governed by treatment duration [41] .
Thus, the recently introduced FOLFOX7 regimen delivers lower doses of 5-FU and higher doses of oxaliplatin over a shorter period of time. Like FOLFOX6, FOLFOX7 is based on the simplified LV-5-FU schedule, but the dose of oxaliplatin is increased. FOLFOX7 comprises 2-hour infusions of oxaliplatin 130 mg/m 2 and LV 400 mg/m 2 , followed by 5-FU bolus 400 mg/m 2 and 46-hour infusion at 2400 mg/m 2 for two consecutive days. The 5-FU bolus is omitted in case of haematological toxicity. An initial report with this bimonthly regimen showed an overall response rate of 44% and a median PFS of 6.3 months in 38 pretreated patients with metastatic disease [42] . In a subset of 29 patients with refractory disease (progression on the same LV-5-FU regimen), the response rate was 52%. Only 9% of patients experienced = grade 3 peripheral neuropathy and 9% developed = grade 3 neutropenia. Only one patient (3%) was withdrawn for toxicity. An oxaliplatin dose intensity of over 100 mg/m 2 /2 weeks was achieved in 79% of patients. Thus, FOLFOX7 appears to limit haematological toxicity, allowing an increase in oxaliplatin dose intensity and higher response rates.
Based on a retrospective analysis of experimental data, Skipper inferred that high-dose intensity for a relatively short duration is the best choice when cure is likely, whereas lower dose intensity for longer periods is the best choice for palliation [27] . Certainly, a potential problem with chemotherapy dose intensification, whether achieved by increasing the dose per cycle or by decreasing the cycle interval, is an increase in toxic effects that have an impact on a patient's quality of life [43] . Achieving the right balance between the benefits of dose-intensification on response and survival, and the risk of adverse effects and reduced quality of life is an important challenge. Increased toxicity and reduced quality of life would be particularly undesirable in a palliative care setting.
Our data show, however, that in pretreated metastatic disease, oxaliplatin dose intensification provides significant advantages in terms of response rate and PFS, without an increase in severe toxicity. The bimonthly FOLFOX regimens have proved to be some of the most effective regimens available for the treatment of metastatic colorectal cancer resistant to LV-5-FU. The insight provided by our analysis into the optimal oxaliplatin dose-intensity should help to further refine the FOLFOX regimen in order to improve outcomes, tolerability and quality of life for patients with advanced colorectal cancer. Further results with FOLFOX7 are eagerly awaited.
